Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2000 Apr;95(4):1051-5.
doi: 10.1111/j.1572-0241.2000.01980.x.

Treatment of mastalgia with tamoxifen in male patients with liver cirrhosis: a randomized crossover study

C P Li  1 , F Y Lee, S J Hwang, F Y Chang, H C Lin, B I Kuo, C J Chu, S D Lee
Affiliations
Clinical Trial

Treatment of mastalgia with tamoxifen in male patients with liver cirrhosis: a randomized crossover study

C P Li et al. Am J Gastroenterol. 2000 Apr.

Abstract

Objective: Mastalgia is occasionally found in patients with liver cirrhosis, especially in those receiving spironolactone for treatment of ascites. The pathogenesis is still unclear. Estrogen excess in cirrhotic patients and estrogenic effects of the spironolactone are possible leading causes. Treatment directed against the preponderance of estrogenic stimulation in these patients has never been investigated. This study was designed to investigate the efficacy and safety of tamoxifen, an estrogen antagonist, on mastalgia in patients with liver cirrhosis.

Methods: A total of 16 male cirrhotic patients with mastalgia were randomly assigned to two groups. One group was treated with tamoxifen (20 mg p.o., b.i.d.) for 1 month, followed by placebo for the next month. The other group was treated in the reverse order. All patients received spironolactone for ascites and/or peripheral edema, and the drug was continued during the study period. The size of the breasts and the degree of breast pain and tenderness were recorded in all subjects before and after the treatment periods. Serum levels of estradiol and testosterone were measured using the radioimmunoassay method.

Results: Of the 16 patients, 14 experienced a decrease or disappearance of the breast pain and/or tenderness during the tamoxifen treatment period, whereas only two of the 16 patients felt an improvement during the placebo period (p < 0.05). There were significant improvements in the breast pain and tenderness scores and decreases in the breast sizes during the tamoxifen treatment period (before vs after: 1.4+/-0.3 vs 0.4+/-0.2, p = 0.002; 1.9+/-0.2 vs 0.5+/-0.2, p < 0.001; and 6.8+/-0.6 vs 5.5+/-0.6 cm, p = 0.02, respectively), whereas no obvious change was seen during the placebo period. Serum levels of estradiol and testosterone did not change significantly after the tamoxifen or placebo treatments (p > 0.05). No major side effects were noted during the therapeutic periods.

Conclusions: Tamoxifen is effective and safe in the management of mastalgia in male cirrhotic patients taking spironolactone.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

  • Guidelines on the management of ascites in cirrhosis.
    Moore KP, Aithal GP. Moore KP, et al. Gut. 2006 Oct;55 Suppl 6(Suppl 6):vi1-12. doi: 10.1136/gut.2006.099580. Gut. 2006. PMID: 16966752 Free PMC article. No abstract available.
  • Ascites.
    Garcia N, Sanyal AJ. Garcia N, et al. Curr Treat Options Gastroenterol. 2001 Dec;4(6):527-537. doi: 10.1007/s11938-001-0018-2. Curr Treat Options Gastroenterol. 2001. PMID: 11696279
  • Treatment of Ascites.
    Choudhury J, Sanyal AJ. Choudhury J, et al. Curr Treat Options Gastroenterol. 2003 Dec;6(6):481-491. doi: 10.1007/s11938-003-0050-5. Curr Treat Options Gastroenterol. 2003. PMID: 14585237
  • Palliative Care for Patients with End-Stage Liver Disease.
    Philips CA, Kedarisetty CK. Philips CA, et al. J Clin Exp Hepatol. 2023 Mar-Apr;13(2):319-328. doi: 10.1016/j.jceh.2022.08.003. Epub 2022 Aug 13. J Clin Exp Hepatol. 2023. PMID: 36950499 Free PMC article. Review.

Publication types

MeSH terms